海螺型材(000619.SZ):擬與慶投集團成立德州海螺 投建年產20萬平方米高端系統門窗項目
格隆匯6月2日丨海螺型材(000619.SZ)公佈,2020年6月1日,公司第八屆董事會第十七次會議審議通過了《關於投資建設年產20萬平米門窗項目的議案》,同意公司在山東省德州市慶雲縣與山東慶投控股集團有限公司(“慶投集團”)共同出資成立“德州海螺建材有限責任公司(籌)”(“德州海螺”),並簽署對應投資合同。
德州海螺註冊資本為4000萬元,其中公司現金出資2400萬元,佔比60%,慶投集團以現金和實物出資1600萬元,佔比40%。
同時,以德州海螺為主體,投資建設年產20萬平方米高端系統門窗項目。公司所需資金來源為自有資金及銀行貸款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.